Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Revenue (2017 - 2025)

Organogenesis Holdings has reported Revenue over the past 9 years, most recently at $225.6 million for Q4 2025.

  • Quarterly results put Revenue at $225.6 million for Q4 2025, up 78.13% from a year ago — trailing twelve months through Dec 2025 was $564.2 million (up 17.04% YoY), and the annual figure for FY2025 was $564.2 million, up 17.04%.
  • Revenue for Q4 2025 was $225.6 million at Organogenesis Holdings, up from $150.9 million in the prior quarter.
  • Over the last five years, Revenue for ORGO hit a ceiling of $225.6 million in Q4 2025 and a floor of $86.7 million in Q1 2025.
  • Median Revenue over the past 5 years was $115.3 million (2022), compared with a mean of $119.9 million.
  • Biggest five-year swings in Revenue: surged 78.65% in 2021 and later dropped 22.44% in 2025.
  • Organogenesis Holdings' Revenue stood at $127.9 million in 2021, then fell by 9.65% to $115.5 million in 2022, then decreased by 13.73% to $99.7 million in 2023, then rose by 27.1% to $126.7 million in 2024, then surged by 78.13% to $225.6 million in 2025.
  • The last three reported values for Revenue were $225.6 million (Q4 2025), $150.9 million (Q3 2025), and $101.0 million (Q2 2025) per Business Quant data.